Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)"

Transcription

1 Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract Type Contract Number Jurisdiction State(s) Palmetto GBA A and B and HHH MAC MAC A J - M South Carolina Palmetto GBA A and B and HHH MAC MAC B J - M South Carolina Palmetto GBA A and B and HHH MAC MAC A J - M Virginia Palmetto GBA A and B and HHH MAC MAC B J - M Virginia Palmetto GBA A and B and HHH MAC MAC A J - M West Virginia Palmetto GBA A and B and HHH MAC MAC B J - M West Virginia Palmetto GBA A and B and HHH MAC MAC A J - M North Carolina Palmetto GBA A and B and HHH MAC MAC B J - M North Carolina Back to Top LCD Information Document Information LCD ID L34426 Previous Proposed LCD DL34426 LCD Title Ophthalmic Angiography (Fluorescein and Indocyanine Green) AMA CPT / ADA CDT / AHA NUBC Copyright Statement CPT only copyright American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 10/24/2016 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 09/08/2016 Notice Period End Date 10/23/2016 The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association. Printed on 11/1/2016. Page 1 of 23

2 UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ( AHA ), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA. Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company. CMS National Coverage Policy Title XVIII of the Social Security Act, 1862 (a)(1)(a) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Title XVIII of the Social Security Act, 1862 (a)(14) defines other than physician services. Title XVIII of the Social Security Act, 1862 (a)(7) excludes routine physical examinations. Title XVIII of the Social Security Act, 1833 (e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim. 42 CFR (a) indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements). 42 CFR defines physician assistant services. 42 CFR defines NPP services. 42 CFR defines clinical nurse services. CMS Internet-Only Manual, Pub , Medicare National Coverage Determinations Manual, Chapter 1, Part 1, 80.2, , 80.3 & Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: Fluorescein Fluorescein angiography is used in the diagnosis and treatment of a wide range of ocular disorders. Its visible fluorescence leaking from damaged vessels makes it particularly useful in the diagnosis of retinal vascular disorders and monitoring treatment of conditions amenable to laser photocoagulation. The dye is injected intravenously and serial photographs are taken through the pupil. While morphological characteristics alone may be pathognomonic of certain disease states, the timing of appearance of the dye in the choroid, in the central retinal artery and in the filling (or otherwise) of the quadrants have diagnostic implications. Indocyanine Green Indocyanine green dye is injected intravenously into the patient to highlight the vessels in the retina and the deeper tissue layer of the choroid. Under infrared light, Indocyanine Green fluoresces allowing the choroidal vessels to be visualized through the retinal pigment epithelium or in the presence of retinal or vitreous hemorrhage that would otherwise obscure visualization. Indocyanine green angiography (ICG) is effective in the diagnosis and treatment of ill-defined choroidal neovascularization (e.g., associated with age related macular degeneration (AMD)). It is also useful in the evalution of feeder vessels, choroidal leakages in the late phase, and ruptures of the pigment epithelium. Indications: Fluorescein Fluorescein angiography with interpretation is medically necessary as an adjunct to the diagnosis of chorioretinal vascular abnormalities especially relating to choroid neovascularization, noninfective vasculitis, and age related Printed on 11/1/2016. Page 2 of 23

3 macular degeneration. It may also be appropriate in evaluating intraocular tumors, visual loss in systemic disease, acute exudative inflammations such as toxoplasmosis and optic disc edema. Medical necessity for such angiography would generally be in the context of a changing clinical picture. Fluorescein angiography may be useful in diabetic retinopathy in identifying ischemia and neovascularization, locating microaneurysms, and defining macular edema. Fluorescein angiography following treatment, for example, of choroidal neovascularization (CNV) is necessary to monitor for recurrence or to detect additional treatable disease. Usually this is performed on the basis of a change in the clinical picture similar to the way it is employed prior to treatment. However, fluorescein angiography may be performed following treatment without clinical change in order to detect occult lesions. This will occur most often in CNV and very rarely in other diseases. Indocyanine Green Indocyanine green angiography (ICG) may be a valuable diagnostic adjunct to fluorescein angiography in the evaluation of the following conditions: Retinal neovascularization Choroid neovascularization Serous detachment of retinal pigment epithelium Hemorrhagic detachment of retinal pigment epithelium Retinal hemorrhage Limitations: Fluorescein Studies performed for screening will be denied by Medicare as not medically necessary. Fluorescein angiography must be performed under the direct supervision (physician present in the office and immediately available) of a physician when done by a non-physician practitioner. If excluded by State law, optometrists may not be reimbursed for fluorescein angiography. Fluorescein angiography of an asymptomatic contralateral without new abnormalities on ophthalmoscopic exam, in patients with unilateral AMD or other disease, will be denied as not medically necessary. Evidence of medical necessity must be documented in the medical record for each. Indocyanine Green Indocyanine green angiography must be performed under the direct supervision (physician present in the office and immediately available) of a physician when done by a non-physician practitioner. If excluded by State law, optometrists may not be reimbursed for ICG angiography. Indocyanine green is formulated with iodine and should not be used on patients who are allergic to iodine. ICG for the evaluation of patients with background diabetic retinopathy is not considered to be a medically necessary service. ICG angiography of an asymptomatic contralateral without new abnormalities on ophthalmoscopic exam, in patients with unilateral AMD or other disease, will be denied as not medically necessary. Evidence of medical necessity must be documented in the medical record for each. Studies performed for screening will be denied by Medicare as not medically necessary. Other Comments: Limitation of liability and refund requirements apply when denials are based on medical necessity. The provider/supplier must notify the beneficiary in writing, prior to rendering the service, if the provider/supplier is aware that the test, item or procedure may not be considered medically necessary by Medicare. The limitation of liability and refund requirements do not apply when the test, item or procedure is statutorily excluded, has no Medicare benefit category or is rendered for screening purposes. For outpatient settings other than CORFs, references to "physicians" throughout this policy include non- Printed on 11/1/2016. Page 3 of 23

4 physicians, such as nurse practitioners, clinical nurse specialists and physician assistants. Such non-physician practitioners, with certain exceptions, may certify, order and establish the plan of care as authorized by State law. (See Section CMS National Coverage Policy). Back to Top Coding Information Bill Type : Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims. N/A Revenue : Contractors may specify Revenue to help providers identify those Revenue typically used to report this service. In most instances Revenue are purely advisory. Unless specified in the policy, services reported under other Revenue are equally subject to this coverage determination. Complete absence of all Revenue indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue. N/A CPT/HCPCS Group 1 Paragraph: N/A Group 1 : FLUORESCEIN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) WITH INTERPRETATION AND REPORT INDOCYANINE-GREEN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) WITH INTERPRETATION AND REPORT ICD-10 that Support Medical Necessity Group 1 Paragraph: The correct use of an ICD-10 code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination. ICD-10 for Fluorescein Angiography (92235) Group 1 : ICD-10 A18.53 Tuberculous chorioretinitis B20 Human immunodeficiency virus [HIV] disease B39.4 Histoplasmosis capsulati, unspecified B39.5 Histoplasmosis duboisii B39.9 Histoplasmosis, unspecified B58.01 Toxoplasma chorioretinitis C69.20 Malignant neoplasm of unspecified retina C69.21 Malignant neoplasm of right retina C69.22 Malignant neoplasm of left retina C69.30 Malignant neoplasm of unspecified choroid C69.31 Malignant neoplasm of right choroid C69.32 Malignant neoplasm of left choroid D18.09 Hemangioma of other sites Printed on 11/1/2016. Page 4 of 23

5 D31.20 Benign neoplasm of unspecified retina D31.21 Benign neoplasm of right retina D31.22 Benign neoplasm of left retina D31.30 Benign neoplasm of unspecified choroid D31.31 Benign neoplasm of right choroid D31.32 Benign neoplasm of left choroid D57.00 Hb-SS disease with crisis, unspecified D57.01 Hb-SS disease with acute chest syndrome D57.02 Hb-SS disease with splenic sequestration D57.1 Sickle-cell disease without crisis D57.20 Sickle-cell/Hb-C disease without crisis D Sickle-cell/Hb-C disease with acute chest syndrome D Sickle-cell/Hb-C disease with splenic sequestration D Sickle-cell/Hb-C disease with crisis, unspecified D57.80 Other sickle-cell disorders without crisis D Other sickle-cell disorders with acute chest syndrome D Other sickle-cell disorders with splenic sequestration D Other sickle-cell disorders with crisis, unspecified D86.0 Sarcoidosis of lung D86.1 Sarcoidosis of lymph nodes D86.2 Sarcoidosis of lung with sarcoidosis of lymph nodes D86.3 Sarcoidosis of skin D86.81 Sarcoid meningitis D86.82 Multiple cranial nerve palsies in sarcoidosis D86.83 Sarcoid iridocyclitis D86.84 Sarcoid pyelonephritis D86.85 Sarcoid myocarditis D86.86 Sarcoid arthropathy D86.87 Sarcoid myositis D86.89 Sarcoidosis of other sites D86.9 Sarcoidosis, unspecified E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left Printed on 11/1/2016. Page 5 of 23

6 E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, E08.36 Diabetes mellitus due to underlying condition with diabetic cataract E08.37X1 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right E08.37X2 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left E08.37X3 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, E08.39 Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left Printed on 11/1/2016. Page 6 of 23

7 E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, E09.36 Drug or chemical induced diabetes mellitus with diabetic cataract E09.37X1 Printed on 11/1/2016. Page 7 of 23

8 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right E09.37X2 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left E09.37X3 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, E09.39 Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left Printed on 11/1/2016. Page 8 of 23

9 E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified E10.37X1 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right E10.37X2 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left E10.37X3 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, E10.39 Type 1 diabetes mellitus with other diabetic ophthalmic complication E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right Printed on 11/1/2016. Page 9 of 23

10 E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, E11.36 Type 2 diabetes mellitus with diabetic cataract E11.37X1 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, E11.39 Type 2 diabetes mellitus with other diabetic ophthalmic complication E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left Printed on 11/1/2016. Page 10 of 23

11 E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, E13.36 Other specified diabetes mellitus with diabetic cataract E13.37X1 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right E13.37X2 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left E13.37X3 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, E13.39 Other specified diabetes mellitus with other diabetic ophthalmic complication E78.00 Pure hypercholesterolemia, unspecified E78.01 Familial hypercholesterolemia E Postprocedural hematoma of an endocrine system organ or structure following an endocrine system procedure E Postprocedural hematoma of an endocrine system organ or structure following other procedure E Postprocedural seroma of an endocrine system organ or structure following an endocrine system procedure E Postprocedural seroma of an endocrine system organ or structure following other procedure G35 Multiple sclerosis G45.3 Amaurosis fugax G93.2 Benign intracranial hypertension H Unspecified focal chorioretinal inflammation, right H Unspecified focal chorioretinal inflammation, left H Unspecified focal chorioretinal inflammation, H Focal chorioretinal inflammation, juxtapapillary, right H Focal chorioretinal inflammation, juxtapapillary, left H Focal chorioretinal inflammation, juxtapapillary, H Focal chorioretinal inflammation of posterior pole, right H Focal chorioretinal inflammation of posterior pole, left H Focal chorioretinal inflammation of posterior pole, H Focal chorioretinal inflammation, peripheral, right H Focal chorioretinal inflammation, peripheral, left H Focal chorioretinal inflammation, peripheral, H Focal chorioretinal inflammation, macular or paramacular, right Printed on 11/1/2016. Page 11 of 23

12 H Focal chorioretinal inflammation, macular or paramacular, left H Focal chorioretinal inflammation, macular or paramacular, H Unspecified disseminated chorioretinal inflammation, right H Unspecified disseminated chorioretinal inflammation, left H Unspecified disseminated chorioretinal inflammation, H Disseminated chorioretinal inflammation of posterior pole, right H Disseminated chorioretinal inflammation of posterior pole, left H Disseminated chorioretinal inflammation of posterior pole, H Disseminated chorioretinal inflammation, peripheral right H Disseminated chorioretinal inflammation, peripheral, left H Disseminated chorioretinal inflammation, peripheral, H Disseminated chorioretinal inflammation, generalized, right H Disseminated chorioretinal inflammation, generalized, left H Disseminated chorioretinal inflammation, generalized, H Acute posterior multifocal placoid pigment epitheliopathy, right H Acute posterior multifocal placoid pigment epitheliopathy, left H Acute posterior multifocal placoid pigment epitheliopathy, H30.21 Posterior cyclitis, right H30.22 Posterior cyclitis, left H30.23 Posterior cyclitis, H Harada's disease, right H Harada's disease, left H Harada's disease, H Other chorioretinal inflammations, right H Other chorioretinal inflammations, left H Other chorioretinal inflammations, H30.91 Unspecified chorioretinal inflammation, right H30.92 Unspecified chorioretinal inflammation, left H30.93 Unspecified chorioretinal inflammation, H Solar retinopathy, right H Solar retinopathy, left H Solar retinopathy, H Choroidal degeneration, unspecified, right H Choroidal degeneration, unspecified, left H Choroidal degeneration, unspecified, H Age-related choroidal atrophy, right H Age-related choroidal atrophy, left H Age-related choroidal atrophy, H Diffuse secondary atrophy of choroid, right H Diffuse secondary atrophy of choroid, left H Diffuse secondary atrophy of choroid, H31.21 Choroideremia H31.29 Other hereditary choroidal dystrophy H Choroidal rupture, right H Choroidal rupture, left H Choroidal rupture, H Hemorrhagic choroidal detachment, right H Hemorrhagic choroidal detachment, left H Hemorrhagic choroidal detachment, H Serous choroidal detachment, right H Serous choroidal detachment, left H Serous choroidal detachment, H32 Chorioretinal disorders in diseases classified elsewhere H Unspecified retinoschisis, right H Unspecified retinoschisis, left H Unspecified retinoschisis, H Cyst of ora serrata, right Printed on 11/1/2016. Page 12 of 23

13 H Cyst of ora serrata, left H Cyst of ora serrata, H Other retinoschisis and retinal cysts, right H Other retinoschisis and retinal cysts, left H Other retinoschisis and retinal cysts, H33.21 Serous retinal detachment, right H33.22 Serous retinal detachment, left H33.23 Serous retinal detachment, H34.01 Transient retinal artery occlusion, right H34.02 Transient retinal artery occlusion, left H34.03 Transient retinal artery occlusion, H34.10 Central retinal artery occlusion, unspecified H34.11 Central retinal artery occlusion, right H34.12 Central retinal artery occlusion, left H34.13 Central retinal artery occlusion, H Retinal artery branch occlusion, right H Retinal artery branch occlusion, left H Retinal artery branch occlusion, H Central retinal vein occlusion, right, with macular edema H Central retinal vein occlusion, right, with retinal neovascularization H Central retinal vein occlusion, right, stable H Central retinal vein occlusion, left, with macular edema H Central retinal vein occlusion, left, with retinal neovascularization H Central retinal vein occlusion, left, stable H Central retinal vein occlusion,, with macular edema H Central retinal vein occlusion,, with retinal neovascularization H Central retinal vein occlusion,, stable H Venous engorgement, right H Venous engorgement, left H Venous engorgement, H Tributary (branch) retinal vein occlusion, right, with macular edema H Tributary (branch) retinal vein occlusion, right, with retinal neovascularization H Tributary (branch) retinal vein occlusion, right, stable H Tributary (branch) retinal vein occlusion, left, with macular edema H Tributary (branch) retinal vein occlusion, left, with retinal neovascularization H Tributary (branch) retinal vein occlusion, left, stable H Tributary (branch) retinal vein occlusion,, with macular edema H Tributary (branch) retinal vein occlusion,, with retinal neovascularization H Tributary (branch) retinal vein occlusion,, stable H34.9 Unspecified retinal vascular occlusion H Exudative retinopathy, right H Exudative retinopathy, left H Exudative retinopathy, H Hypertensive retinopathy, right H Hypertensive retinopathy, left H Hypertensive retinopathy, H Retinal micro-aneurysms, unspecified, right H Retinal micro-aneurysms, unspecified, left H Retinal micro-aneurysms, unspecified, H Retinal neovascularization, unspecified, right H Retinal neovascularization, unspecified, left H Retinal neovascularization, unspecified, H Retinal vasculitis, right H Retinal vasculitis, left H Retinal vasculitis, H Retinal telangiectasis, right H Retinal telangiectasis, left H Retinal telangiectasis, Printed on 11/1/2016. Page 13 of 23

14 H35.09 Other intraretinal microvascular abnormalities H35.21 Other non-diabetic proliferative retinopathy, right H35.22 Other non-diabetic proliferative retinopathy, left H35.23 Other non-diabetic proliferative retinopathy, H35.33 Angioid streaks of macula H Macular cyst, hole, or pseudohole, right H Macular cyst, hole, or pseudohole, left H Macular cyst, hole, or pseudohole, H Cystoid macular degeneration, right H Cystoid macular degeneration, left H Cystoid macular degeneration, H Puckering of macula, right H Puckering of macula, left H Puckering of macula, H Toxic maculopathy, right H Toxic maculopathy, left H Toxic maculopathy, H35.52 Pigmentary retinal dystrophy H35.53 Other dystrophies primarily involving the sensory retina H35.54 Dystrophies primarily involving the retinal pigment epithelium H35.61 Retinal hemorrhage, right H35.62 Retinal hemorrhage, left H35.63 Retinal hemorrhage, H Central serous chorioretinopathy, right H Central serous chorioretinopathy, left H Central serous chorioretinopathy, H Serous detachment of retinal pigment epithelium, right H Serous detachment of retinal pigment epithelium, left H Serous detachment of retinal pigment epithelium, H Hemorrhagic detachment of retinal pigment epithelium, right H Hemorrhagic detachment of retinal pigment epithelium, left H Hemorrhagic detachment of retinal pigment epithelium, H35.81 Retinal edema H35.82 Retinal ischemia H43.89 Other disorders of vitreous body H43.9 Unspecified disorder of vitreous body H44.21 Degenerative myopia, right H44.22 Degenerative myopia, left H44.23 Degenerative myopia, H46.01 Optic papillitis, right H46.02 Optic papillitis, left H46.03 Optic papillitis, H Ischemic optic neuropathy, right H Ischemic optic neuropathy, left H Ischemic optic neuropathy, H47.10 Unspecified papilledema H Drusen of optic disc, right H Drusen of optic disc, left H Drusen of optic disc, H Pseudopapilledema of optic disc, right H Pseudopapilledema of optic disc, left H Pseudopapilledema of optic disc, H Other disorders of optic disc, right H Other disorders of optic disc, left H Other disorders of optic disc, M Rheumatoid myopathy with rheumatoid arthritis of right shoulder M Rheumatoid myopathy with rheumatoid arthritis of left shoulder Printed on 11/1/2016. Page 14 of 23

15 M Rheumatoid myopathy with rheumatoid arthritis of right elbow M Rheumatoid myopathy with rheumatoid arthritis of left elbow M Rheumatoid myopathy with rheumatoid arthritis of right wrist M Rheumatoid myopathy with rheumatoid arthritis of left wrist M Rheumatoid myopathy with rheumatoid arthritis of right hand M Rheumatoid myopathy with rheumatoid arthritis of left hand M Rheumatoid myopathy with rheumatoid arthritis of right hip M Rheumatoid myopathy with rheumatoid arthritis of left hip M Rheumatoid myopathy with rheumatoid arthritis of right knee M Rheumatoid myopathy with rheumatoid arthritis of left knee M Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot M Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot M05.49 Rheumatoid myopathy with rheumatoid arthritis of multiple sites M Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of right hand M Rheumatoid polyneuropathy with rheumatoid arthritis of left hand M Rheumatoid polyneuropathy with rheumatoid arthritis of right hip M Rheumatoid polyneuropathy with rheumatoid arthritis of left hip M Rheumatoid polyneuropathy with rheumatoid arthritis of right knee M Rheumatoid polyneuropathy with rheumatoid arthritis of left knee M Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot M Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot M05.59 Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites M Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement M05.79 Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement M Other rheumatoid arthritis with rheumatoid factor of right shoulder M Other rheumatoid arthritis with rheumatoid factor of left shoulder M Other rheumatoid arthritis with rheumatoid factor of right elbow M Other rheumatoid arthritis with rheumatoid factor of left elbow M Other rheumatoid arthritis with rheumatoid factor of right wrist M Other rheumatoid arthritis with rheumatoid factor of left wrist M Other rheumatoid arthritis with rheumatoid factor of right hand M Other rheumatoid arthritis with rheumatoid factor of left hand M Other rheumatoid arthritis with rheumatoid factor of right hip M Other rheumatoid arthritis with rheumatoid factor of left hip M Other rheumatoid arthritis with rheumatoid factor of right knee M Other rheumatoid arthritis with rheumatoid factor of left knee M Other rheumatoid arthritis with rheumatoid factor of right ankle and foot Printed on 11/1/2016. Page 15 of 23

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmoscopy (L34017) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmoscopy (L34017) Document Information Local Coverage Determination (LCD): Ophthalmoscopy (L34017) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract

More information

Jurisdiction New Mexico. Retirement Date N/A

Jurisdiction New Mexico. Retirement Date N/A Local Coverage Determination (LCD): Chiropractic Services (L34816) Contractor Information Contractor Name Novitas Solutions, Inc. opens in new Contract Number 04212 Contract Type A and B MAC J - H LCD

More information

Local Coverage Determination (LCD): RAST Type Tests ( L30524 )

Local Coverage Determination (LCD): RAST Type Tests ( L30524 ) Page 2 of 6 Local Coverage Determination (LCD): RAST Type Tests ( L30524 ) Contractor Information Contractor Name Novitas Solutions, Inc. Contract Number 12502 Contract Type A and B MAC LCD Information

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Local Coverage Article for Chiropractic Services (A47798) Contractor Information. Article Information. Contractor Name. Contractor Numbers

Local Coverage Article for Chiropractic Services (A47798) Contractor Information. Article Information. Contractor Name. Contractor Numbers Local Coverage Article for Chiropractic Services (A47798) Print Contractor Information Contractor Name Novitas Solutions, Inc. Contractor Numbers 12501, 12502, 12101, 12102, 12201, 12202, 12301, 12302,

More information

LCD Information Document Information LCD ID Number L30046

LCD Information Document Information LCD ID Number L30046 Local Coverage Determination (LCD): Pathology and Laboratory: B-type Natriuretic Peptide (BNP) Testing (L30046) LCD Information Document Information LCD ID Number L30046 LCD Title Pathology and Laboratory:

More information

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy MolDX: HLA-DQB1*06:02 Testing for Narcolepsy CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the

More information

Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice)

Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice) Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice) Print Contractor Information Contractor Name Novitas Solutions, Inc. Contractor Numbers 04911, 07101, 07102, 07201,

More information

Contractor Number Oversight Region Region IV

Contractor Number Oversight Region Region IV Local Coverage Determination (LCD) for Hospice - Renal Care (L31538) Contractor Information Contractor Name Palmetto GBA opens in new window Contractor Number 11004 Contractor Type HHH MAC LCD Information

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A Local Coverage Determination (LCD): Chiropractic Services (L35424) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

ICD-10-CM Are You Prepared? Part IV Posterior Segment

ICD-10-CM Are You Prepared? Part IV Posterior Segment ICD-10-CM Are You Prepared? Part IV Posterior Segment Rebecca H. Wartman OD April 2014 With contributions from Doug Morrow OD & Harvey Richman OD Overview This webinar will provide an introduction to ICD-10-CM

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Document Information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Document Information FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective

More information

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors Ophthalmologic Policy UnitedHealthcare Commercial Drug Policy Vascular Endothelial Growth Factor (VEGF) Inhibitors Policy Number: 2016D0042H Effective Date: October 1, 2016 Table of Contents Page INSTRUCTIONS

More information

Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891)

Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891) Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891) Links in PDF documents are not guaranteed to work. To follow a web link, please

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A Local Coverage Determination (LCD): Bone Mass Measurement (L36460) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

ICD-10-CM Are you Prepared? Disclaimers for Presentation. Disclaimers for Presentation 5/13/2014. What is ICD-10-CM/PCS

ICD-10-CM Are you Prepared? Disclaimers for Presentation. Disclaimers for Presentation 5/13/2014. What is ICD-10-CM/PCS AOA Third Party Center Coding Experts Are you Prepared? Rebecca H. Wartman O.D. Optometry s Meeting 2014 With contributions from Doug Morrow O.D. & Harvey Richman O.D. Rebecca H. Wartman, O.D Douglas C.

More information

Disease-Specific Fluorescein Angiography

Disease-Specific Fluorescein Angiography Ruth E. Picchiottino, CRA Disease-Specific Fluorescein Angiography 15 Disease-Specific Fluorescein Angiography Recommendations for tailoring retinal fluorescein angiography to diabetic retinopathy, macular

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127 Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

b. To facilitate the management decision of a patient with an equivocal stress test.

b. To facilitate the management decision of a patient with an equivocal stress test. National Imaging Associates, Inc. Clinical guidelines EBCT HEART CT & HEART CT CONGENITAL CCTA CPT4 Codes: 75571 EBCT 75572, 75573 Heart CT & Heart CT Congenital 75574 - CCTA LCD ID Number: L33559 J K

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective

More information

Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute

Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates

More information

Implementing New & Revised ICD-10 Codes

Implementing New & Revised ICD-10 Codes Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates cgreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates

More information

UVEITIS. Dr. Yılmaz ÖZYAZGAN

UVEITIS. Dr. Yılmaz ÖZYAZGAN UVEITIS Dr. Yılmaz ÖZYAZGAN UVEITIS DEFINITION BY STRICT DEFINITION, UVEITIS IS AN INFLAMMATION OF UVEAL TRACT. BUT IN PRACTICAL, IT IS GENERALLY NOT RESTRICTED TO THE UVEA AND INVOLVES OTHER ADJACENT

More information

Professional CGM Reimbursement Guide

Professional CGM Reimbursement Guide Professional CGM Reimbursement Guide 2015 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................

More information

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES A. GENERAL PROVISIONS 1. Eye Examination Benefits Optometric benefits are services defined in Section 23 of the Medical and Health Care Services Regulations,

More information

Professional CGM Reimbursement Guide

Professional CGM Reimbursement Guide Professional CGM Reimbursement Guide 2017 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Blepharoplasty, Eyelid Surgery, and Brow Lift (L33765)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Blepharoplasty, Eyelid Surgery, and Brow Lift (L33765) Local Coverage Determination (LCD): Blepharoplasty, Eyelid Surgery, and Brow Lift (L33765) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor

More information

Therapeutic Shoes for Diabetics

Therapeutic Shoes for Diabetics Last Review Date: August 11, 2017 Number: MG.MM.DM.03bC8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Ophthalmology Coding: Raise Your Eye-Q. Nancy Clark, CPC, COC, CPB, CPMA, CPC-I

Ophthalmology Coding: Raise Your Eye-Q. Nancy Clark, CPC, COC, CPB, CPMA, CPC-I Ophthalmology Coding: Raise Your Eye-Q Nancy Clark, CPC, COC, CPB, CPMA, CPC-I 1 Disclaimer The information in this presentation was current at the time the presentation was compiled. Always consult CPT,

More information

Since /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office

Since /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist SELARL CABINET DOCTEUR GONZALEZ 27, Boulevard des Minimes 31 200 Toulouse! 05 34 40 77 30 e-mail : cabinet.dr.gonzalez@wanadoo.fr Fax

More information

3/6/2014 ICD Are we close to being ready? Technician Meeting 2014 ISEPS/COS Annual Meeting March 7, 2014

3/6/2014 ICD Are we close to being ready? Technician Meeting 2014 ISEPS/COS Annual Meeting March 7, 2014 Technician Meeting 2014 ISEPS/COS Annual Meeting March 7, 2014 Presented by Joy Newby, LPN, CPC, PCS Newby Consulting, Inc. 5725 Park Plaza Court Indianapolis, IN 46220 Voice: 317.573.3960 Fax: 866-631-9310

More information

Misdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (CSC)

Misdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (CSC) HPTER 12 Misdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (S) linical Features VKH disease is a bilateral granulomatous panuveitis often associated with exudative

More information

LCD for Omalizumab (Xolair ) (L29240)

LCD for Omalizumab (Xolair ) (L29240) LCD for Omalizumab (Xolair ) (L29240) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29240 LCD Information

More information

MEDICAL POLICY SUBJECT: TRANSPUPILLARY THERMOTHERAPY

MEDICAL POLICY SUBJECT: TRANSPUPILLARY THERMOTHERAPY MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283

Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

FLORIDA MEDICARE PART B LOCAL MEDICAL REVIEW POLICY

FLORIDA MEDICARE PART B LOCAL MEDICAL REVIEW POLICY FLORIDA MEDICARE PART B LOCAL MEDICAL REVIEW POLICY CPT/HCPCS Codes 93925 Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study 93926 unilateral or limited study Policy

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Local Coverage Determination (LCD): Drugs and Biologicals: Botulinum Toxins (L34253) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Bevacizumab (Avastin)

Bevacizumab (Avastin) Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:

More information

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION INDICATIONS: Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. It is caused by

More information

Local Coverage Determination (LCD) for Cardiac Catheterization (L29090)

Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD

More information

Case report. Goldmann tonometer were 12 and 15 mmhg respectively. The Amsler grid test was positive OD.

Case report. Goldmann tonometer were 12 and 15 mmhg respectively. The Amsler grid test was positive OD. Romanian Journal of Ophthalmology, Volume 59, Issue 1, January-March 2015. pp:63-67 CASE REPORT POSTERIOR UVEITIS OR WET AGE -RELATED MACULAR DEGENERATION? CASE REPORT Filip Mircea, Moisescu Raluca *Ama

More information

Experience Spectacular Retinal Imaging with the new NIDEK F-10 Digital Ophthalmoscope

Experience Spectacular Retinal Imaging with the new NIDEK F-10 Digital Ophthalmoscope Experience Spectacular Retinal Imaging with the new NIDEK F-10 Digital Ophthalmoscope The F-10 was developed to give Ophthalmologists a high definition (HD) diagnostic imaging system. Designed to provide

More information

MEDICAL POLICY SUBJECT: TRANSPUPILLARY THERMOTHERAPY. POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: TRANSPUPILLARY THERMOTHERAPY. POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: TRANSPUPILLARY EDITED DATE: 08/20/15, 08/18/16, 08/17/17 PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.

More information

ICD-10-CM. Test Your Knowledge Chapter 6. Using your ICD-10-CM codebook, code the following:

ICD-10-CM. Test Your Knowledge Chapter 6. Using your ICD-10-CM codebook, code the following: ICD-10-CM Test Your Knowledge Chapter 6 Using your ICD-10-CM codebook, code the following: 1) Anorexia nervosa 2) Attention deficit disorder 3) Moderate pyromania 4) Narcissistic personality 5) Chronic

More information

2017 Clinical Quality Measures

2017 Clinical Quality Measures 2017 Clinical Quality Measures Clinical quality measures, or CQMs, are statistics that seek to quantify the quality of services performed by health care providers. These statistics involve data related

More information

Clinical Policy: Cardiac Biomarker Testing for Acute Myocardial Infarction Reference Number: CP.MP.156

Clinical Policy: Cardiac Biomarker Testing for Acute Myocardial Infarction Reference Number: CP.MP.156 Clinical Policy: Reference Number: CP.MP.156 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important regulatory and legal information. Description The

More information

Lumify. Lumify reimbursement guide {D DOCX / 1

Lumify. Lumify reimbursement guide {D DOCX / 1 Lumify Lumify reimbursement guide {D0672917.DOCX / 1 {D0672917.DOCX / 1 } Contents Overview 4 How claims are paid 4 Documentation requirements 5 Billing codes for ultrasound: Non-hospital setting 6 Billing

More information

Magnetic Resonance Imaging (NCD 220.2)

Magnetic Resonance Imaging (NCD 220.2) Policy Number 220.2 Approved By UnitedHealthcare Medicare Committee Current Approval Date 05/14/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare Medicare

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): Urinalysis Policy (L34060) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name

More information

ICD-10-CM is coming Be Ready!

ICD-10-CM is coming Be Ready! ICD-10-CM is coming Be Ready! Rebecca H. Wartman OD Harvey B. Richman OD FAAO FCOVD North Carolina State Optometric Society 2015 Disclaimers for Presentation 1.All information was current at time it was

More information

Abstract title: Vision loss from myelinated retinal nerve fiber layer with maculopathy. Authors: Man Kin (Eric) Chow, OD Lori Vollmer, OD, FAAO

Abstract title: Vision loss from myelinated retinal nerve fiber layer with maculopathy. Authors: Man Kin (Eric) Chow, OD Lori Vollmer, OD, FAAO Abstract title: Vision loss from myelinated retinal nerve fiber layer with maculopathy. Authors: Man Kin (Eric) Chow, OD Lori Vollmer, OD, FAAO Joseph Sowka, OD, FAAO General Topic: Ocular Disease Primary

More information

Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist

Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, DMLA in particular Installation year

More information

MACULAR DEGENERATION VITREO RETINAL SURGEONS LLC THOMAS G. WARD D.O.

MACULAR DEGENERATION VITREO RETINAL SURGEONS LLC THOMAS G. WARD D.O. MACULAR DEGENERATION VITREO RETINAL SURGEONS LLC THOMAS G. WARD D.O. INTRODUCTION If you are reading this document, it is probable that you, or someone close to you, has been diagnosed as having some form

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Magnetic Resonance Imaging of the Orbit, Face, and/or Neck (L34425)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Magnetic Resonance Imaging of the Orbit, Face, and/or Neck (L34425) Local Coverage Determination (LCD): Magnetic Resonance Imaging of the Orbit, Face, and/or Neck (L34425) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

CMS Limitations Guide MRA Radiology Services

CMS Limitations Guide MRA Radiology Services CMS Limitations Guide MRA Radiology Services Starting July 1, 2008, CMS has placed numerous medical necessity limits on tests and procedures. This reference guide provides you with all of the latest changes.

More information

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION

More information

Vitrectomy for Diabetic Cystoid Macular Edema

Vitrectomy for Diabetic Cystoid Macular Edema Vitrectomy for Diabetic Cystoid Macular Edema Yukihiro Sato, Zeon Lee and Hiroyuki Shimada Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan Purpose: We evaluated visual outcomes

More information

Swept-Source Optical Coherence Tomography

Swept-Source Optical Coherence Tomography Swept-Source Optical Coherence Tomography A Color Atlas This page intentionally left blank Swept-Source Optical Coherence Tomography A Color Atlas Kelvin Y.C. Teo Wong Chee Wai Andrew S.H. Tsai Daniel

More information

Outline. Preventing & Treating Diabetes Related Blindness. Eye Care Center Doctors. Justin Kanoff, MD. Eye Care Center of Northern Colorado

Outline. Preventing & Treating Diabetes Related Blindness. Eye Care Center Doctors. Justin Kanoff, MD. Eye Care Center of Northern Colorado Outline Preventing & Treating Diabetes Related Blindness Justin Kanoff, MD Eye Care Center of Northern Colorado 303 974 4302 Introduction to Eye Care Center of Northern Colorado How the eye works Eye problems

More information

LCD for Interferon (L29202)

LCD for Interferon (L29202) LCD for Interferon (L29202) Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B Contractor Information LCD ID Number L29202 LCD Information LCD Title

More information

Eye injection treatment costs and rebates

Eye injection treatment costs and rebates Eye injection treatment costs and rebates This fact sheet provides general information on the bill you receive from your ophthalmologist for eye injections for the management of wet macular degeneration,

More information

3rd Party News: 2018 ICD-10 CM Edition

3rd Party News: 2018 ICD-10 CM Edition 2018 ICD-10 Special Edition of the NOA 3rd Party Newsletter Page 1 Use CNTRL- F to search for a specific diagnosis, term, or ICD code. CONTENTS Refractive Error Pg.2. Lids and Lashes Pg.2. Cornea Pg.3.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Voretigene Neparvovec-rzyl (Luxturna) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: voretigene_neparvovec_rzyl_luxturna 1/2018 N/A 6/2018 2/2018 Description

More information

Ocular Pathology. I. Congenital and/or developmental. A. Trisomy 21. Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea)

Ocular Pathology. I. Congenital and/or developmental. A. Trisomy 21. Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea) I. Congenital and/or developmental Robbins Pathologic Basis of Disease, 6 th Ed. A. Trisomy 21 Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea) Focal hypoplasia of iris Cataracts frequently

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Intravitreal Implant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravitreal_implant 11/2010 6/2017 6/2018 6/2017 Description of Procedure or Service

More information

ATLAS OF OCT. Retinal Anatomy in Health & Pathology by Neal A. Adams, MD. Provided to you by:

ATLAS OF OCT. Retinal Anatomy in Health & Pathology by Neal A. Adams, MD. Provided to you by: ATLAS OF OCT Retinal Anatomy in Health & Pathology by Neal A. Adams, MD Provided to you by: Atlas of OCT The OCT Atlas is written by Neal A. Adams, MD, and produced by Heidelberg Engineering, Inc. to help

More information

ICD 10 CM OPHTHALMOLOGY 2017 Quick Reference Guide SYMPTOMS CATARACT/LENS. with status migrainosus... G43.801

ICD 10 CM OPHTHALMOLOGY 2017 Quick Reference Guide SYMPTOMS CATARACT/LENS. with status migrainosus... G43.801 ICD 10 CM OPHTHALMOLOGY 2017 Quick Reference Guide SYMPTOMS Blurred vision (368.8)... H53.8 Contusion of eyeball and orbital tissues (921.3) eye initial encounter... S05.11XA subsequent encounter... S05.11XD

More information

Learn Connect Succeed. JCAHPO Regional Meetings 2015

Learn Connect Succeed. JCAHPO Regional Meetings 2015 Learn Connect Succeed JCAHPO Regional Meetings 2015 What Allied Staff Needs to Know to Prepare for ICD-10 Financial Interest JCAHPO Palm Beach June 26-27, 2015 Presented by: E. Ann Rose E. Ann Rose is

More information

Ocular imaging in acquired retinopathy with multiple myeloma

Ocular imaging in acquired retinopathy with multiple myeloma Ocular imaging in acquired retinopathy with multiple myeloma ABDELRAHMAN GABER SALMAN MD- FRCS (GLASG)- MRCS (ED) ASSOCIATE PROFESSOR AIN SHAMS UNIVERSITY EVRS 2015 Immunogammopathies Immunogammopathies

More information

FUTURE DRAFT Local Coverage Determination for Chemodenervation (DL31701)

FUTURE DRAFT Local Coverage Determination for Chemodenervation (DL31701) FUTURE DRAFT Local Coverage Determination for Chemodenervation (DL31701) http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=32955&... Page 1 of 14 Search Home Medicare Medicaid

More information

Fundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose:

Fundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose: IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. XII (Feb. 2016), PP 80-88 www.iosrjournals.org Fundus Fluorescein Angiography in Diabetic

More information

Jurisdiction Nebraska. Retirement Date N/A

Jurisdiction Nebraska. Retirement Date N/A If you wish to save the PDF, please ensure that you change the file extension to.pdf (from.ashx). Local Coverage Determination (LCD): BONE Mass Measurement (L31620) Contractor Information Contractor Name

More information

Fundamentals of Retina Coding

Fundamentals of Retina Coding Fundamentals of Retina Coding Presented by: Joy Woodke, COE, OCS Sunday, April 2, 2017 ASRS Business of Retina Meeting Dallas, TX American Academy of Ophthalmic Executives Financial Disclosure Joy Woodke,

More information

Central serous chorioretinopathy (CSCR) was

Central serous chorioretinopathy (CSCR) was Case Report 777 Perfluorocarbon Liquid-Assisted External Drainage in the Management of Central Serous Chorioretinopathy with Bullous Serous Retinal Detachment Hung-Chiao Chen, MD; Jau-Der Ho, MD; San-Ni

More information

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MP.049.MH Visually Evoked Response Test This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP MedStar CareFirst

More information

Office Based Practice. Vitreoretinal Disease & Surgery. Coding Fiesta Vitreoretinal Disease & Surgery September 23, 2017 ADULT RETINA

Office Based Practice. Vitreoretinal Disease & Surgery. Coding Fiesta Vitreoretinal Disease & Surgery September 23, 2017 ADULT RETINA Vitreoretinal Disease & Surgery Coding Fest 2017 Vitreoretinal Surgery & Disease University of FL College of Medicine ADULT RETINA Medical Retina Surgical Retina Age Related Vascular Disease Vascular Disease

More information

LCD for Sargramostim (GM-CSF, Leukine ) (L29275)

LCD for Sargramostim (GM-CSF, Leukine ) (L29275) LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: CP.PHAR.93

Clinical Policy: Bevacizumab (Avastin) Reference Number: CP.PHAR.93 Clinical Policy: (Avastin) Reference Number: CP.PHAR.93 Effective Date: 12/11 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Coding Terminology Getting Back To The Basics. Financial Interest. Getting Back To The Basics. Rose & Associates

Coding Terminology Getting Back To The Basics. Financial Interest. Getting Back To The Basics. Rose & Associates Coding Terminology Getting Back To The Basics ASCRS ASOA Symposium & Congress Administrator Program Boston, Massachusetts April 25-29, 2014 Presented by: Patricia Kennedy, COMT, CPC, COE Financial Interest

More information

2016 PQRS Recommended Measures for: Ophthalmology

2016 PQRS Recommended Measures for: Ophthalmology Measures Groups Choose 1 Measures Group Report on a minimum of 20 eligible patients (at least 11 must be Medicare Part B FFS patients) #130: Documentation of Current Medications in the Medical Record #226:

More information

2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1

2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 GE Healthcare 2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 February 2017 www.gehealthcare.com/reimbursement This advisory addresses Medicare coding, coverage and

More information

TYPES. Full thickness defect in the sensory retina (break) Secondary to Tumour, Inflammation or a Systemic disease

TYPES. Full thickness defect in the sensory retina (break) Secondary to Tumour, Inflammation or a Systemic disease Dr.A.Divya Introduction Definition : Retinal deatchment is the separation of the neurosensory retina(nsr) from the retinal pigment epithelium(rpe) ; results in the accumulation of subretinal fluid(srf)

More information

Grand Rounds: Interesting and Exemplary Cases From Guanajuato and Djibouti

Grand Rounds: Interesting and Exemplary Cases From Guanajuato and Djibouti Learning Community: January 25, 2015 Grand Rounds: Interesting and Exemplary Cases From Guanajuato and Djibouti JORGE CUADROS, OD, PHD EyePACS In Guanajuato Program started in 2007 Cameras go from clinic

More information

LCD L Bariatric Surgical Management of Morbid Obesity

LCD L Bariatric Surgical Management of Morbid Obesity LCD L32619 - Bariatric Surgical Management of Morbid Obesity Contractor Information Contractor Name: Novitas Solutions, Inc. Contractor Number(s): 04911, 07101, 07102, 07201, 07202, 07301, 07302, 04111,

More information

Fluorescein and Indocyanine Green Videoangiography of Choroidal Melanomas

Fluorescein and Indocyanine Green Videoangiography of Choroidal Melanomas luorescein and Indocyanine Green Videoangiography of Choroidal Melanomas Leyla S. Atmaca, igen Batioğlu and Pelin Atmaca Eye Clinic, Ankara University Medical School, Ankara, Turkey Purpose: This study

More information

Prothrombin Time (PT)

Prothrombin Time (PT) Other Names/Abbreviations PT 190.17 - Prothrombin Time (PT) Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the Partial Thromboplastin Time (PTT), Prothrombin

More information